Chinese Medical E-ournals Database

Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition) ›› 2011, Vol. 07 ›› Issue (05): 476 -480. doi: 10.3877/cma.j.issn.1673-5250.2011.05.020

Review

Research Progress of 1-Deamino-8-D-Arginine-Vasopressin in the Treatment of Patients With Hemophilia

Song-ting BAI, Guang-yao SHENG   

  1. Department of Pediatrics, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
  • Published:2011-10-01
  • Supported by:
    * Project No. 200801004, supported by the Science and Technical Project of the Ministry of Health

1-deamino-8-D-arginine-vasopressin (DDAVP) is a synthetic compound of the antidiuretic hormone vasopressin, which can increase plasma concentration of factor Ⅷ (FⅧ), von Willebrand factor (vWF), and tissue plasminogen activator (t-PA) in normal subjects and patients with hemophilia A(HA). It has been using for the treatment or prevention of bleeding episodes caused by mild HA and type 1 von Willebrand disease (vWD) over the past 30 years on aboard. More and more studies have demonstrated the clinical efficacy of DDAVP for carriers of female HA, patients of HA with inhibitors and acquired HA, even for patients with haemophilia B(HB). DDAVP is safe, cheap and carries no risk of transmitting of blood-borne viral infections particularly during the human immunodeficiency virus (HIV) and hepatitis virus, and developing inhibitor antibodies upon repeated treatments with FⅧ concentrates. Thus, in every patient with newly diagnosed as hemophilia, a test infusion/injection of DDAVP should be carried out to assess the future usefulness of the compound.

1 Castaman G. Desmopressin for the treatment of haemophilia [J]. Haemophilia, 2008, 14(Suppl 1): 15-20.
2 Castaman G, Mancuso ME, Giacomelli SH, et al. Molecular and phenotypic determinants of response to desmopressin in adult patients with mild hemophilia A[J]. J Thromb Hemost, 2009,7:1824-1831.
3 Kaufmann JE, Oksche A, Wollllheim CB, et al. Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP[J]. J Clin Invest, 2000, 106:107-116.
4 Federici AB. The use of desmopressin in von Willebrand disease:The experience of the first 30 years(1977-2007)[J]. Haemophilia, 2008, 14(Suppl 1):5-14.
5 Franchini M, Zaffanello M, Lippi G. The use of desmopressin in mild hemophilia A[J]. Blood Coagul Fibrinolysis, 2010, 21(7):615-619.
6 Lethagen S, Harris AS, Nilsson IM. Intranasal desmopressin (DDAVP) by spray in mild hemophilia A and von Willebrand's disease type I[J]. Blut, 1990, 60: 187-191.
7 Rodeghiero F, Castaman G, DiBona E, et al. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand' s disease and hemophilia A [ J]. Blood, 1989, 74: 1997-2000.
8 Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP) [J]. Br J Haematol, 1992, 82: 87-93.
9 Ozgonenel B, Rajpurkar M, Lusher JM. How do you treat bleeding disorders with desmopressin [J]? Postgrad Med J, 2007, 83(977):159-163.
10 Franchini M, Mannucci PM. Co-morbidities and quality of life in elderly persons with hemophilia [J]. Br J Hematol, 2010, 148:522-533.
11 Franchini M, Favaloro EJ, Lippi G. Mild hemophilia A [ J]. J Thromb Hemost, 2010, 8(3): 421-432.
12 Franchini M, Zaffanello M, Lippi G. The use of desmopressin in mild hemophilia A[J]. Blood Coagul Fibrinolysis, 2010, 21(7):615-619.
13 Lethagen S. Desmopressin in mild hemophilia A: Indications, limitations, efficacy, and safety [J]. Semin Thromb Hemost, 2003, 29: 101-106.
14 Castaman G, Mancuso ME, Giacomelli SH, et al. Molecular and phenotypic determinants of response to desmopressin in adult patients with mild hemophilia A[J]. J Thromb Haemost, 2009, 7: 1824-1831.
15 Riccardi F, Rivolta GF, Franchini M, et al. Characterization of a novel mutation in the F8 promoter region associated with mild hemophilia A and resistance to DDAVP therapy[J]. J Thromb Haemost, 2009, 7: 1234-1235.
16 De la Fuente B, Kasper CK, Rickles FR, et al. Response of patients with mild and moderate hemophilia A and von Willebrand's disease to treatment with desmopressin [J]. Ann Intern Med, 1985, 103: 6-14.
17 Leissinger C, Becton D, Cornell C, et al. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A[J]. Haemophilia, 2001, 7: 258-266.
18 Mannucci PM. Use of desmopressin (DDAVP) during early pregnancy in factor Ⅷ-deficient women [J]. Blood, 2005, 105:3382.
19 Nolan B, White B, Smith J, O'Reilly C, et al. Desmopressin: Therapeutic limitations in children and adults with inherited coagulation disorders[J]. Br J Haematol, 2000, 109: 865-869.
20 Revel-Vilk S, Blanchette V, Sparling C, et al. DDAVP challenge tests in boys with mild/moderate haemophilia A [J]. Br J Haematol, 2002, 117: 947-951.
21 Sharathkumar A, Lillicrap D, Blanchette VS, et al. Intensive exposure to factor Ⅷ is a risk factor for inhibitor development in mild hemophilia A[J]. J Thromb Haemost, 2003, 1: 1228-1236.
22 Shima M. Diagnosis and treatment of acquired hemophilia [J]. Rinsho Ketsueki, 2010, 51: 1531-1538.
23 Ehl S, Severin T, Sutor HS. DDAVP (desmopressin; 1-deaminocys-8-d-arginine-vasopressin) treatment in children with haemophilia B[J]. Br J Haematol, 2000, 111: 1260-1262.
24 Federici AB. The use of desmopressin in von Willebrand disease:The experience of the first 30 years(1977-2007)[J]. Haemophilia, 2008, 14(Suppl 1): 5-14.
25 Castaman G, Lethagen S, Federici AB, et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (vWD): Results from the European Study MCMDM-1 vWD[J]. Blood, 2008, 111(7): 3531-3539.
26 Castaman G, Eikenboom JCJ, Rodeghiero F, et al. A novel candidate mutation (Arg 611→His) in type 1 "platelet discordant" von Willebrand's disease with desmopressin-induced thrombocytopenia [J]. Br J Haematol, 1995, 89: 656-659.
27 Federici AB, Rand JH, Bucciarelli P, et al. Acquired von Willebrand syndrome: Data from an international registry [J]. Thromb Haemost, 2000, 84: 345-349.
[1] Zhantao Liu, Yanqiu Song. Targeted therapy for breast cancer[J]. Chinese Journal of Breast Disease(Electronic Edition), 2021, 15(06): 329-336.
[2] Yuyan Deng, Yonghui Pang, Qinguo Mo, Honghong Tan, Chuanlan Mao, Feifei Chen. Effect of neoadjuvant chemotherapy on complications and coagulation function after modified radical mastectomy[J]. Chinese Journal of Breast Disease(Electronic Edition), 2021, 15(05): 283-287.
[3] The Joint Surgery Branch of the Chinese Orthopedic Association, Guangdong’s Medical Association of Osteoporosis And Bone Mineral Research, Foshan Shunde 3rd Peoele’s Hospital. Clinical intervention guideline for using of anti-osteoporosis drugs in postoperative fragile hip fractures in China (2023 Edition)[J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(06): 751-764.
[4] Changjiao Sun, Pingping Xu, Lanlan Xie, Huimin Li, Kai Yang, Xu Cai, Lianxu Chen. Surgical challenges of total knee arthroplasty in patients with hemophilia[J]. Chinese Journal of Joint Surgery(Electronic Edition), 2022, 16(06): 771-775.
[5] Hongxi Shang, Jinglong He, Min Hao, Qiang Ding, Wei Sun, Anqing Liu, Wei Xie. Clinical effect of total knee arthroplasty in treatment of severe hemophilic arthritis cases[J]. Chinese Journal of Joint Surgery(Electronic Edition), 2021, 15(06): 753-757.
[6] Qing Hu, Haiyan Yu. Fetal intrauterine therapy and evaluation of the risk[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(01): 23-30.
[7] Zeying Jiang, Anting Wang, Jiaoli Wang, Ci Chen, Qiuling Zhou, Yanjuan Huang, Fang Zhou, Yan Xue, Jianfeng Zhou, Wenyong Tan, Meifang Du. Effect of multiple plant oils combination in preventing the chemoradiotherapy induced toxicities[J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2023, 18(06): 523-527.
[8] Changying Ye, Jing Xie, Guicong Ding. Research advances in interim treatment of deciduous tooth caries[J]. Chinese Journal of Stomatological Research(Electronic Edition), 2023, 17(05): 365-370.
[9] Xijuan Chen, Juan Xia. The treatment progress of the oral lichen planus[J]. Chinese Journal of Stomatological Research(Electronic Edition), 2022, 16(04): 203-207.
[10] Bitao Wang, Zheng Wang, Guobin Wang. Treatment status and progress of Lynch syndrome[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(03): 332-335.
[11] Chengren Zhang, Xiongfei Yang, Binbin Du, Lili Liu, Jingjing Li, Chengzhang Zhu, Dewang Wu, Yaochun Lv. A meta-analysis of primary tumor resection in asymptomatic colorectal cancer with unresectable metastases[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(03): 305-310.
[12] Yiming Nadire, Hong Cui, Yasheng Nuerbiya, Abudureyimu Zulaiyati, Abulajiang Zulikaimaier, Mijiti Maimaitili. Epigenetic advances in glioma[J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2021, 11(05): 309-315.
[13] Guoying Zhu, Li Chen, Ling She, Jie Bai, Yongnian Ding, Fengshang Zhu. Therapeutic reality and dilemma of microecological modulators in patients with non-alcoholic fatty liver disease[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(01): 1-4.
[14] Chunyuan Luo, Hangxin Liu, Yue Li, Yanmei Mai, Lingbo Shi. Postpartum acquired hemophilia A: a case report and review of the literature[J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2023, 11(02): 114-117,123.
[15] Zhenzhong Li, Liqun Feng, Qingbian Ma, Tao Wang, Yongqiu Li, Bin Zhao, Xiuchuan Qin, Qingxi Li, Shizheng Wu, Hongbin Sun, Jun Yuan, Lan Chu, Jian Wu, Yuxiang Gu, Jimao Peng, Zhi Chen, Dongsheng Fan. Interpretation of 2020 expert consensus statement on neuroprotection after cardiac arrest in China (Ⅲ): drug therapy[J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2021, 15(06): 356-360.
Viewed
Full text


Abstract